NCT03440892

Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients

Longitudinal Observational Study on Rheumatoid Arthritis Patients: Effects of Antirheumatic Treatment on Serum Levels of Survivin

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 2,500 (estimated)
• Sponsor: Vastra Gotaland Region · Other Government
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

To validate the utility of survivin as a biomarker of pharmacological response to therapeutic intervention in rheumatoid arthritis patients.

Detailed description

In a prospective observational study the investigators aim to study the ability of modern antirheumatic treatments to suppress levels of survivin in sera. Rheumatoid arthritis patients scheduled to start new pharmacological treatment will be followed for a period of 6 months. No intervention or influence on choice of treatment will be performed, the decision of new/other medication is entirely made by the patient and their rheumatologist. The study entails addition of survivin analyse (1 vial of sera) before and after start of new treatment. Data concerning survivin levels, disease activity and other clinical parameters before and after start of new treatment will also be analysed. The patients will leave sera for survivin analyse at baseline and 3 and 6 months after start of new treatment.

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	methotrexate	folate antagonist
DRUG	sulfasalazine	Immunomodulatory
DRUG	abatacept	Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
DRUG	tocilizumab	IL-6 receptor antagonist
DRUG	tofacitinib/baricitinib	JAK inhibitor

Timeline

• Start date: 2017-11-01
• Primary completion: 2025-01-01
• Completion: 2025-01-01
• First posted: 2018-02-22
• Last updated: 2022-05-04

Locations

1 site across 1 country: Sweden